[go: up one dir, main page]

EP3383387B1 - Composition vétérinaire comprenant cbd et/ou thc pour une utilisation dans le traitement du stress chez les abeilles - Google Patents

Composition vétérinaire comprenant cbd et/ou thc pour une utilisation dans le traitement du stress chez les abeilles

Info

Publication number
EP3383387B1
EP3383387B1 EP16870112.6A EP16870112A EP3383387B1 EP 3383387 B1 EP3383387 B1 EP 3383387B1 EP 16870112 A EP16870112 A EP 16870112A EP 3383387 B1 EP3383387 B1 EP 3383387B1
Authority
EP
European Patent Office
Prior art keywords
composition
veterinary composition
veterinary
cannabinoid
beehive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16870112.6A
Other languages
German (de)
English (en)
Other versions
EP3383387A1 (fr
EP3383387A4 (fr
Inventor
Aharon M. Eyal
Netta LIN-COHEN
Youval LIN
Meir Ariel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canna B Cure Ltd
Original Assignee
Canna B Cure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canna B Cure Ltd filed Critical Canna B Cure Ltd
Publication of EP3383387A1 publication Critical patent/EP3383387A1/fr
Publication of EP3383387A4 publication Critical patent/EP3383387A4/fr
Application granted granted Critical
Publication of EP3383387B1 publication Critical patent/EP3383387B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Definitions

  • compositions and specifically treatment methods and compositions for bees.
  • the productivity of bees can be very sensitive to such things as viruses, stress, etc. This can show itself in many ways, such as, for example, amount of honey produced per a particular bee hive. Accordingly, there is a constant search in this area for ways to address these issues.
  • PCT Publication No. WO 2017/072704 discloses therapeutic compositions comprising honey, at least one cannabinoid, and water at a concentration of less than 26%wt.
  • PCT Publication No. WO 2017/013661 discloses a bee ingestible composition comprising a bee food base and THC and/or CBD.
  • PCT Publication No. WO 2015/143536 discloses honey mite disruptive compounds.
  • PCT Publication No. WO 97/47193 discloses a method for the control of infestations of honeybee colonies by applying to the bee-hives an effective amount of an essential oil in a slow-release formulation.
  • a veterinary composition comprising at least one cannabinoid comprising CBD and/or THC, optionally an extract of cannabis plant material; for use in the treatment of stress in bees at or near a bee hive.
  • the veterinary composition additionally contains an additive selected from the group consisting of emulsifiers, antioxidants, sugars, pollen, pollen substitutes, pollen supplements, omega-3 fatty acids, vegetable oil, minerals, vitamins, fats, essential oils, invertase enzyme and combinations thereof.
  • an additive selected from the group consisting of emulsifiers, antioxidants, sugars, pollen, pollen substitutes, pollen supplements, omega-3 fatty acids, vegetable oil, minerals, vitamins, fats, essential oils, invertase enzyme and combinations thereof.
  • the veterinary composition additionally contains an additive selected from the group consisting of compounds characteristic to eucalyptus flowers, compounds characteristic to avocado flowers, compounds characteristic to orange blossom, compounds characteristic to wild flowers, characteristic to Tribulus terrestris and combinations thereof.
  • the veterinary composition is for administering by vaporizing the composition in the beehive, spraying the composition into the atmosphere of the beehive, spraying the composition on honeycombs in the beehive, spraying the composition on brood-containing honeycombs, incorporating the composition into beeswax used to form the beehive frames or combination thereof.
  • the veterinary composition is for administering to the bees when present at or near a beehive containing brood cells, wherein the count of brood cells in said beehive, the count of sealed brood cells in said beehive or both is at least 10% greater than those in a beehive under the same conditions receiving no veterinary composition treatment.
  • the composition is for administration to bees during winter.
  • the composition is contained in an aerosol, spray and/or vapor.
  • cannabinoid(s) refers to both cannabinoid(s) in carboxylic acid form and cannabinoids in decarboxylated form. The same is true for each cannabinoid, e.g. THC and CBD.
  • non-cannabinoid cannabis compound refers to a non-cannabinoid compound present in at least one strain of cannabis plants.
  • terpene refers to compounds comprising at least one isoprene unit.
  • the terms “terpene” and “terpenoid” are used herein interchangeably.
  • terpene other than cannabis terpenes refers to a terpene that is not common to or typically doesn't exist in cannabis plants.
  • flavonoid other than cannabis flavonoids refers to a flavonoid that is not common to or typically doesn't exist in cannabis plants.
  • extract of a non-cannabis plant refers to any product of extracting a plant other than a cannabis plant.
  • carrier refers to any non-cannabis compound.
  • non-cannabis compound refers to compounds not present in cannabis plant or present there at concentration of less than 5%.
  • cannabis plant material refers to material derived from a cannabis plant.
  • pollen As used herein, the terms pollen, pollen substitutes and pollen supplements refer to protein-containing feed ingredients, whether containing flower pollen or not.
  • honeycomb As used herein, the terms “honeycomb”, “honeycomb frames”, and “frames” are interchangeable.
  • administering a composition to bees refers to dispensing or applying the composition in a way that makes the composition available to bees, to bees brood and/or to bees pathogens.
  • invert sugar and inverted sugar refer to the product of sucrose hydrolysis (into glucose and fructose) e.g. the result of treating sucrose with the enzyme invertase.
  • honey refers to concentrated sugar compositions referred to commercially as honey and excludes cannabis extract as such.
  • a comprising honey refers to comprising components of commercial pure honey (sugars, amino acids, organic acids, furfurals, vitamins, minerals).
  • commercial pure honey refers to unadulterated honey sold globally at a rate of at least one ton per year.
  • excipient refers to a compound used to formulate an active ingredient.
  • a veterinary composition comprising at least one cannabinoid comprising CBD and/or THC, and optionally an extract of cannabis plant material, for use in the treatment of bees at or near a bee hive.
  • treating comprises administering, dispensing or supplying said veterinary composition to the bees in combination with bees feed, or with bees feed additives or with both.
  • the term in combination with refers to incorporated in, blended with or administering concurrently with .
  • bees keepers feed the bees sugar solution as an energy source during the time when nectar supply is insufficient to support the activity, e.g. before spring starts.
  • the solutions are of 50-60% sugar and contain, sucrose, glucose, fructose, high-fructose corn syrup, inverted sugar or combinations thereof.
  • the veterinary composition is blended with the sugar solution before feeding it to the bees or during feeding.
  • said veterinary composition is administered in combination with each one of the sugar feeding.
  • said veterinary composition is administered in combination with each one of the sugar feeding, whereby the veterinary composition is evenly consumed and/or evenly enhancing performance in the bee hive.
  • bees keepers feed bees with a protein ingredient, such as pollen, pollen substitutes, pollen supplements.
  • a protein ingredient such as pollen, pollen substitutes, pollen supplements.
  • the veterinary composition is blended with the protein ingredient before feeding it to the bees or during feeding. Any source of pollen is suitable, including cannabis pollen.
  • said veterinary composition is administered in combination with each one of the protein feeding.
  • said veterinary composition is administered in combination with each one of the protein feeding, whereby the veterinary composition is evenly consumed and/or evenly enhancing performance in the bee hive.
  • administering the veterinary composition comprises vaporizing the composition in the beehive, spraying the composition into the atmosphere of the beehive, spraying the composition on honeycombs in the beehive, spraying the composition on brood-containing honeycombs, incorporating the composition into beeswax used to form the beehive frames or combination thereof.
  • said veterinary composition is administered to the bees between 2 and 12 times per year, between 2 and 10, between 3 and 9, between 3 and 8 or between 3 and 6.
  • said veterinary composition is administered to the bees during winter, during spring or within several weeks (e.g. within 4-6 weeks) before blooming start is predicted.
  • said veterinary composition is administered to the bees during shortage in food, during times of negative energy balance in the hive (more energy is used than provided) during high pathogens content, during times when ambient temperature is lower than 25°C, lower than 20°C lower than 15°C, or lower than 10°C or during times when ambient temperature is higher than 35°C.
  • treating comprises administering to the bees between 1 milligram (mg) and 1000 milligram veterinary composition per beehive, between 1.5mg and 400mg, between 2mg and 300mg or between 2.5mg and 200mg.
  • treating comprises administering to the bees between 0.1mg and 300mg cannabinoid per bee hive, between 0.2mg and 200mg, between 0.3mg and 150mg or between 0.5mg and 100mg.
  • treating comprises administering to the bees between 0.1mg and 300mg non-cannabinoid cannabis compounds per bee hive, between 0.2mg and 200mg, between 0.3mg and 150mg or between 0.5mg and 100mg.
  • said veterinary composition comprises at least two cannabinoids, at least three, at least four or at least five. According to an embodiment, said veterinary composition comprises at least three non-cannabinoid cannabis compounds, at least four, at least five, at least six or at least ten.
  • said veterinary composition comprises tetrahydrocannabinol (THC), cannabidiol (CBD) or both.
  • said veterinary composition comprises both THC and CBD at a weight/weigh ratio between 30:1 and 1:30, between 20:1 and 1:20, or between 10:1 and 1:10.
  • said veterinary composition includes at least one terpene, at least two, at least three non-cannabinoid cannabis compounds, at least four, at least five, at least six or at least ten. According to an embodiment, said veterinary composition includes at least one flavonoid, at least two, at least three non-cannabinoid cannabis compounds, at least four or at least five.
  • said non-cannabinoid cannabis compounds comprise non-cannabinoid cannabis compounds characteristic to Sativa cannabis strains and/or to Indica strains.
  • said non-cannabinoid cannabis compounds comprise non-cannabinoid cannabis compounds characteristic to Sativa cannabis strains.
  • said non-cannabinoid cannabis compounds comprise non-cannabinoid cannabis compounds characteristic to Indica cannabis strains.
  • characteristic to such strains recited is meant that the compounds are typically contained in each of the strains recited in an amount serving to identify it as associated with such strain, but not exclusively contained in such strain, i.e., may also be present in other of the strains as well.
  • said veterinary composition comprises an extract of cannabis plant material, e.g. as formed in contacting said plant material with an extractant, and/or as formed by distilling components out of said plant material, e.g. as in steam distillation.
  • Any extractant is suitable.
  • said extractant is ethanol, a hydrocarbon, carbon dioxide or a combination thereof.
  • said veterinary composition additionally contains an emulsifier and/or an antioxidant.
  • said veterinary composition further comprises a compound selected from the group consisting of mono-glycerides, diglycerides, lecithin, gums (e.g. xanthan gum) and polysaccharides.
  • said veterinary composition is lipophilic in nature and is administered in a blend with an aqueous solution and said emulsifier is selected to enable homogeneous dispersion of the veterinary composition in said aqueous solution.
  • said emulsifier is food approved, biological and/or natural.
  • said veterinary composition comprises an antioxidant, whereby said veterinary composition is better protected during prolonged storage.
  • said veterinary composition additionally contains an additive selected from the group consisting of sugars, pollen, pollen substitutes, pollen supplements, polyunsaturated fatty acids, omega-3 fatty acids from various sources, vegetable oil (e.g. coconut oil), minerals, vitamins, fats, essential oils, naringin, beeswax, invertase enzyme and combinations thereof.
  • said veterinary composition additionally contains a pharmaceutical.
  • said pharmaceutical comprises antibiotics.
  • said pharmaceutical is selected from oxytetracyline and dabicycline.
  • the content of said at least one cannabinoid reduces the required amount of pharmaceutical compared with veterinary compositions containing the same pharmaceutical, but without inclusion of any cannabinoids.
  • said veterinary composition administrated to bees comprise antibiotics at an amount of less than 60mg per beehive, less than 50mg, less than 40mg, less than 30mg or less than 20mg.
  • said veterinary composition additionally contains an additive selected from the group consisting of compounds characteristic to eucalyptus flowers, compounds characteristic to avocado flowers, compounds characteristic to orange blossom, compounds characteristic to wild flowers, characteristic to Tribulus terrestris and combinations thereof.
  • characteristic to such flowers and materials recited is meant that the compounds are typically contained in each of the flowers and materials recited in an amount serving to identify it as associated with such flower or material, but not exclusively contained in such material, i.e., may also be present in other of the flowers and materials recited as well.
  • a carrier comprises at least one of a sugar, honey, beeswax, pollen, pollen substitutes, pollen supplements, a protein ingredient, vegetable oil and fiber.
  • said carrier comprises a sugar selected from the group consisting of sucrose, glucose, fructose, high fructose corn syrup, invert sugar and combinations thereof.
  • said carrier comprises honey.
  • said carrier comprises sugar and honey.
  • said carrier comprises an aqueous solution of at least one sugar.
  • said carrier comprises an aqueous solution of glucose and fructose.
  • said carrier comprises an aqueous solution of inverted sugar.
  • sugars concentration in said aqueous solution is in the range between 20% and 80, between 30% and 70% or between 45% and 65%,
  • said carrier comprises solid sugar.
  • said carrier comprises solid sugar powder.
  • said carrier comprises a protein preparation or protein-containing plant material.
  • said carrier comprises a mixture of pollen and sugar.
  • said veterinary composition is characterized by being homogenous or of consistent composition.
  • said at least one cannabinoid is homogeneously dispersed in said carrier.
  • homogeneously dispersed means consistently distributed.
  • at least two samples of at least about 500mg each, taken from said veterinary second composition have similar concentrations of said at least one cannabinoid, e.g. within 10% difference.
  • at least two samples of at least about 500mg each, taken from said veterinary second composition comprising multiple cannabinoids have similar concentrations of multiple (e.g. at least 2, at least 3, at least 5 or at least 10) cannabinoid, e.g. within 10% difference (e.g.
  • the concentration of cannabinoid A in one sample is similar to the concentration of cannabinoid A in another sample and the concentration of cannabinoid B in one sample is similar to the concentration of cannabinoid B in another sample).
  • said at least two non-cannabinoid cannabis compounds are homogeneously dispersed in said carrier.
  • at least two samples of at least about 500mg each, taken from said veterinary second composition have similar concentrations of said at least two non-cannabinoid cannabis compounds, e.g. within 10% difference.
  • said veterinary composition includes a cannabinoid and the weight ratio between said carrier and said cannabinoid is greater than 5, greater than 8, greater than 15, greater than 20, greater than 25, greater than 30, greater than 40, greater than 50, greater than 60, or greater than 80.
  • said veterinary second composition includes non-cannabinoid cannabis compounds and the weight ratio between said carrier and said non-cannabinoid cannabis compounds is greater than 5, greater than 8, greater than 15, greater than 20, greater than 25, greater than 30, greater than 40, greater than 50, greater than 60, or greater than 80.
  • said veterinary composition comprises at least 0.001% by weight cannabinoid, at least 0.001% by weight non-cannabinoid cannabis compounds and at least 40% by weight carrier. According to an embodiment, it comprises at least 0.001% by weight cannabinoid, at least 0.002%, at least 0.004%, at least 0.006%, at least 0.008%, at least 0.01%, at least 0.02%, at least 0.03%, at least 0.04%, at least 0.06%, at least 0.08%, at least 0.1%, at least 0.2%, at least 0.4%, at least 0.6%, at least 0.8% or at least 1%.
  • said veterinary second composition comprises at least 0.001% by weight non-cannabinoid cannabis compounds, at least 0.002%, at least 0.004%, at least 0.006%, at least 0.008%, at least 0.01%, at least 0.02%, at least 0.03%, at least 0.04%, at least 0.06%, at least 0.08%, at least 0.1%, at least 0.2%, at least 0.4%, at least 0.6%, at least 0.8% or at least 1%.
  • said veterinary second composition comprises at least 45% by weight carrier, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80% or at least 85%.
  • said veterinary composition includes a cannabinoid and water and the weight ratio between the water and said cannabinoid is greater than 5, greater than 8, greater than 15, greater than 20, greater than 25, greater than 30, greater than 40, greater than 50, greater than 60, or greater than 80.
  • said veterinary second composition includes non-cannabinoid cannabis compounds and water and the weight ratio between the water and said non-cannabinoid cannabis compounds is greater than 5, greater than 8, greater than 15, greater than 20, greater than 25, greater than 30, greater than 40, greater than 50, greater than 60, or greater than 80.
  • said veterinary composition comprises at least one cannabinoid and/or at least two non-cannabinoid cannabis compounds, at least 40% by weight sugar and at least 40% by weight water; at least one cannabinoid, at least 40% by weight sugar and at least 40% by weight water; at least two non-cannabinoid cannabis compounds, at least 40% by weight sugar and at least 40% by weight water; or at least one cannabinoid, at least two non-cannabinoid cannabis compounds, at least 40% by weight sugar and at least 40% by weight water.
  • said at least one cannabinoid and/or said at least two non-cannabinoid cannabis compounds are homogeneously dispersed in said carrier; said at least one cannabinoid is homogeneously dispersed in said carrier; said at least two non-cannabinoid cannabis compounds are homogeneously dispersed in said carrier; or said at least one cannabinoid and said at least two non-cannabinoid cannabis compounds are homogeneously dispersed in said carrier.
  • said veterinary composition comprises at least one cannabinoid and/or at least two non-cannabinoid cannabis compounds and additionally containing pollen, pollen substitutes and/or pollen supplements. Any source of pollen is suitable, including cannabis pollen.
  • said veterinary second composition includes at least one cannabinoid and/or at least two non-cannabinoid cannabis compounds and additionally contains 30% protein.
  • said veterinary composition additionally contains an emulsifier and/or an antioxidant.
  • said emulsifier is food approved, biological and/or natural.
  • said veterinary second composition further comprises a compound selected from the group consisting of mono-glycerides, diglycerides, lecithin, gums (e.g. xanthan gum) and polysaccharides.
  • said veterinary second composition comprises an antioxidant, whereby said veterinary second composition is better protected during prolonged storage.
  • said veterinary composition additionally contains an additive selected from the group consisting of sugars, pollen, pollen substitutes, pollen supplements, omega- polyunsaturated fatty acids, 3 fatty acids from various sources, vegetable oil (e.g. coconut oil), minerals, vitamins, fats, essential oils, beeswax, naringin, invertase enzyme, and combinations thereof.
  • said veterinary second composition additionally contains a pharmaceutical.
  • said pharmaceutical comprises antibiotics.
  • said pharmaceutical is selected from oxytetracyline and dabicycline.
  • said veterinary composition additionally contains an additive, e.g. a terpene, selected from the group consisting of compounds characteristic to eucalyptus flowers, compounds characteristic to avocado flowers, compounds characteristic to orange blossom, compounds characteristic to wild flowers, characteristic to Tribulus terrestris and combinations thereof.
  • an additive e.g. a terpene, selected from the group consisting of compounds characteristic to eucalyptus flowers, compounds characteristic to avocado flowers, compounds characteristic to orange blossom, compounds characteristic to wild flowers, characteristic to Tribulus terrestris and combinations thereof.
  • characteristic to such flowers and materials recited is meant that the compounds are typically contained in each of the flowers and materials recited in an amount serving to identify it as associated with such flower or material, but not exclusively contained in such material, i.e., may also be present in other of the flowers and materials recited as well.
  • said veterinary composition further comprises at least 10ppm terpene other than cannabis terpenes, at least 50ppm, at least 100ppm, at least 500ppm, at least 1000ppm, at least 3000ppm, at least 5000ppm or at least 10000ppm.
  • said veterinary composition further comprises at least one excipient.
  • said excipient is said carrier.
  • said at least one cannabinoid and at least two non-cannabinoid cannabis compounds are homogeneously dispersed in said carrier and said veterinary second composition comprises said homogeneous dispersion and at least one excipient.
  • said excipient coats said homogeneous dispersion.
  • said veterinary composition is in solid form, in liquid form, in aerosol form, in gel form, in tablet form or in a capsule form.
  • an aerosol comprising said veterinary second composition.
  • a solid preparation comprising said veterinary second composition.
  • a liquid preparation comprising said veterinary second composition.
  • said veterinary composition is administered to the bees between 2 and 12 times per year, between 2 and 10, between 3 and 9, between 3 and 8 or between 3 and 6.
  • said veterinary second composition is administered to the bees during winter, during spring or within several weeks (e.g. within 4-6 weeks) before blooming start is predicted.
  • said veterinary second composition is administered to the bees during shortage in food, during times of negative energy balance in the hive (more energy is used than provided) during high pathogens content, during times when ambient temperature is lower than 25°C, lower than 20°C lower than 15°C, or lower than 10°C or during times when ambient temperature is higher than 35°C.
  • the extract was mixed with honey to form extract-honey mixtures and those extract-honey mixtures were mixed with the 55% sucrose solution.
  • honey 30-50 grams honey as such or after dilution with 10% water, 20% water or 30% water, was warmed to 45°C.
  • the extract was gradually added, while thoroughly mixing. Mixing was continued for 30 minutes after the addition is completed, whereby extract-honey mixtures were formed.
  • the 55% sucrose solution was gradually added to the extract-honey mixtures until the desired overall cannabinoid concentration was reached.
  • the weight/weight ratio between honey and the sucrose solution were in the range between 1:10 and 1:1000. At all tested cannabinoid concentrations, up to several thousand parts per million, the formed final solutions were homogeneous.
  • Example 3 Production of the veterinary composition
  • Example 2 The working method of Example 2 was used to prepare veterinary compositions containing 55% sucrose, honey and extract. In preparing the veterinary composition, the weight/weight ratio between honey and the sucrose solution was 1:20. Three types of veterinary composition were prepared according to Table 2. Table 2: Veterinary compositions Veterinary composition Source [1] Cannabinoid concentration (ppm) THC CBD A Extract 1 2 41 B Extract 2 41 C Extract 1 + Extract 2 20.5 20.5 [1] Source of cannabinoids and of non-cannabinoid cannabis compounds
  • Example 4 Administering the veterinary compositions
  • veterinary compositions For administering the veterinary compositions to bees at or near a bee hive, freshly prepared veterinary compositions, containing the desired amounts of cannabinoids and of non-cannabinoid cannabis compounds, were mixed with 55% sucrose solution to form feeds. The feeds were provided to the bees in feeding trays. The majority of the feed was consumed within several hours.
  • Eighteen bee hives were selected and randomly divided into three groups - Group 1, Group 2 and Group 3 - each one containing six hives. All hives were positioned at the same location in a field at Kfar Bilu, Israel.
  • Example 6 Feeds for the various groups
  • Table 3 Feeding schedule and details Group 1 Group 2 Group 3 1 st feeding Date Feed amount per hive (Kg)(kilograms) 3 3 3 Cannabinoid per hive 3mg CBD 3mg THC 0 Non-cannabinoid [1] per hive 2mg 2mg 0 2 nd feeding Date Feed amount per hive (Kg) 3 3 3 Cannabinoid per hive 1.5mg CBD + 1.5mg THC 3mg THC 0 Non-cannabinoid [1] per hive 2mg 2mg 0 3 rd feeding Date Feed amount per hive (Kg) 3 3 3 3 Cannabinoid per hive 6.7mg CBD 6.7mg THC 0 Non-cannabinoid [1] per hive 4.4mg 4.4mg 0 4 th feeding Date Feed amount per hive (Kg) 3 3 3 Cannabinoid per hive
  • Table 4 summarizes the average number of full honeycombs per hive at the checking dates. Table 4: Average number of full honeycombs per hive Full honeycombs per hive Group 1 Group 2 Group 3 Date Feb 5, 2016 6.2 5.2 6 Feb 16, 2016 8.3 6.4 7.8 March 6, 2016 9.8 9.2 9.7 March 14, 2016 14 15.5 11.3 March 22, 2016 18 17.4 11.3 April 5, 2016 22.4 21.2 14.2 May 2, 2016 23.6 21.3 18.7
  • Table 5 Average amount of harvested honey per hive Harvested honey per hive (Kg) Group 1 Group 2 Group 3 1 st harvest 22.7 18.1 14.8 2 nd harvest 16.6 18.9 12.1 Total 39.3 37.0 26.9
  • the average amount of harvested honey is another indication of improved performance on administering few milligrams of cannabinoid and/or few milligrams of non-cannabinoid cannabis compounds per bee hive.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (7)

  1. Composition vétérinaire comprenant
    au moins un cannabinoïde comprenant le CBD et/ou le THC, éventuellement un extrait de matière végétale de cannabis ;
    destinée à être utilisée dans le traitement du stress chez les abeilles au niveau ou à proximité d'une ruche.
  2. Composition vétérinaire destinée à être utilisée selon la revendication 1, ladite composition vétérinaire contenant en outre un additif choisi dans le groupe constitué d'émulsifiants, d'antioxydants, de sucres, de pollen, de substituts de pollen, de suppléments de pollen, d'acides gras oméga-3, d'huile végétale, de minéraux, de vitamines, de graisses, d'huiles essentielles, d'enzyme invertase et de combinaisons de ceux-ci.
  3. Composition vétérinaire destinée à être utilisée selon la revendication 1, ladite composition vétérinaire contenant en outre un additif choisi dans le groupe constitué de composés caractéristiques des fleurs d'eucalyptus, de composés caractéristiques des fleurs d'avocat, de composés caractéristiques de la fleur d'oranger, de composés caractéristiques des fleurs sauvages, de composés caractéristiques du tribule terrestre et de combinaisons de ceux-ci.
  4. Composition vétérinaire destinée à être utilisée selon la revendication 1, destinée à être administrée par vaporisation de la composition dans la ruche, par pulvérisation de la composition dans l'atmosphère de la ruche, par pulvérisation de la composition sur des nids d'abeilles dans la ruche, par pulvérisation de la composition sur des nids d'abeilles contenant un couvain, par incorporation de la composition dans la cire d'abeille utilisée pour former les cadres de ruche ou par une combinaison de celles-ci.
  5. Composition vétérinaire destinée à être utilisée selon la revendication 1, destinée à être administrée aux abeilles lorsqu'elles sont présentes au niveau ou à proximité d'une ruche contenant des cellules de couvain, dans laquelle le nombre de cellules de couvain dans ladite ruche, le nombre de cellules de couvain scellées dans ladite ruche ou les deux est/sont supérieur(s) d'au moins 10 % à celui/ceux d'une ruche dans les mêmes conditions ne recevant aucun traitement de composition vétérinaire.
  6. Composition vétérinaire destinée à être utilisée selon la revendication 1, ladite composition étant destinée à être administrée aux abeilles pendant l'hiver.
  7. Composition vétérinaire destinée à être utilisée selon la revendication 1, ladite composition étant contenue dans un aérosol, un vaporisateur et/ou une vapeur.
EP16870112.6A 2015-12-05 2016-12-05 Composition vétérinaire comprenant cbd et/ou thc pour une utilisation dans le traitement du stress chez les abeilles Active EP3383387B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263617P 2015-12-05 2015-12-05
PCT/IB2016/057368 WO2017093986A1 (fr) 2015-12-05 2016-12-05 Composition vétérinaire et ses procédés de production et d'utilisation

Publications (3)

Publication Number Publication Date
EP3383387A1 EP3383387A1 (fr) 2018-10-10
EP3383387A4 EP3383387A4 (fr) 2019-08-14
EP3383387B1 true EP3383387B1 (fr) 2025-11-05

Family

ID=58796458

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16870112.6A Active EP3383387B1 (fr) 2015-12-05 2016-12-05 Composition vétérinaire comprenant cbd et/ou thc pour une utilisation dans le traitement du stress chez les abeilles

Country Status (4)

Country Link
US (1) US10675252B2 (fr)
EP (1) EP3383387B1 (fr)
IL (1) IL259755B (fr)
WO (1) WO2017093986A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017013661A1 (fr) 2015-07-22 2017-01-26 Phytopharma International Ltd. Compositions consommables par les abeilles, procédés d'utilisation de ces compositions pour la production de miel, et miel produit par ces procédés
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2019070885A1 (fr) * 2017-10-03 2019-04-11 Spirulinex, Llc Procédés de préparation de compositions à base de plantes encapsulées, solubilisables, produits à base de celles-ci
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
EP3864000A4 (fr) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. Synthèse du cannabigérol
US11723892B2 (en) * 2019-04-08 2023-08-15 Medpharm Holdings, Llc Brain health formulation
US12220397B2 (en) * 2019-04-08 2025-02-11 Medpharm Holdings, Llc Brain health formulation
JP7699852B1 (ja) 2023-12-25 2025-06-30 株式会社秋田屋本店 養蜂用巣礎、及び養蜂用巣礎の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180140644A1 (en) * 2015-07-22 2018-05-24 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038081B1 (es) 1991-12-30 1994-02-01 Pozuelo Herguido Palmira Procedimiento para la obtencion de composiciones ansioliticas a base de valeriana.
GB9612403D0 (en) 1996-06-13 1996-08-14 Sandoz Ltd Organic compounds
FR2850866B1 (fr) 2003-02-06 2007-04-20 Seppic Sa Melange de latex inverse auto-inversible et d'une poudre a usage cosmetique ou pharmaceutique; utilisation comme agent de texture
HUP0400982A2 (en) 2004-05-17 2006-08-28 Chemor Kutato New veterinary product for honeybees
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
RO122437B1 (ro) 2006-07-13 2009-06-30 Institutul De Cercetare-Dezvoltare Pentru Apicultură S.A. Compoziţie apifitoterapeutică de uz veterinar
GB2451254A (en) 2007-07-24 2009-01-28 Gw Pharma Ltd Cannabidiol for use in the treatment of neurodegenerative conditions
US8642645B2 (en) 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids
PL232463B1 (pl) * 2012-02-06 2019-06-28 Merial Inc Miękka, nadająca się do żucia kompozycja weterynaryjna do leczenia i/lub zapobiegania infekcji lub inwazji pasożytniczej u zwierzęcia oraz jej zastosowanie
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
WO2015143536A1 (fr) 2014-03-24 2015-10-01 Simon Fraser University Composés ayant un effet perturbateur sur un acarien de l'abeille et leurs procédés d'utilisation
US9186386B2 (en) * 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
CN105012684A (zh) 2015-08-05 2015-11-04 郑州诺必隆生物科技有限公司 一种治疗家禽葡萄球菌病的中药组合物
EP3368033A4 (fr) 2015-10-31 2019-06-26 Canabuzz-Med Composition thérapeutique à base de miel et de cannabinoïde

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180140644A1 (en) * 2015-07-22 2018-05-24 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby

Also Published As

Publication number Publication date
US10675252B2 (en) 2020-06-09
US20180344662A1 (en) 2018-12-06
IL259755B (en) 2022-06-01
EP3383387A1 (fr) 2018-10-10
EP3383387A4 (fr) 2019-08-14
CA3007393A1 (fr) 2017-06-08
WO2017093986A1 (fr) 2017-06-08
IL259755A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
EP3383387B1 (fr) Composition vétérinaire comprenant cbd et/ou thc pour une utilisation dans le traitement du stress chez les abeilles
US10617722B2 (en) Honey-cannabinoid therapeutic composition
US9867859B2 (en) Method for increasing cannabinol content in a lipid-based extract of cannabis
US11426434B2 (en) Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US11839601B2 (en) Cannabis-enriched enzymatically treated therapeutic composition
EP3737241B1 (fr) Compositions nutritionnelles solides à activité acaricide pour l'apiculture pour utilisation dans la prophylaxie et le traitement d'infestations par varroa
CA2953700C (fr) Aliments pour insectes
US20210205236A1 (en) Therapeutic combinations of boswellia extract and cannabinoids
CN102631405A (zh) 一种复方芹菜素纳米乳抗高血压药物
KR20120122072A (ko) 꿀벌응애 방제용 겔 조성물
Prokhoda et al. Quality management of the apiproduct from the drone larvae
KR102540346B1 (ko) 꿀벌 유인용 조성물 및 이를 포함하는 양봉용 약물 전달 시스템
SU1653678A1 (ru) Подкормка дл пчел
CN101982176A (zh) 兽用复方亚硒酸钠-维生素e口服纳米乳制剂与制备方法
CA2902766A1 (fr) Methode de croissance et de recolte et traitement de chanvre de sorte que la fraction classee comme graine ait la teneur therapeutique de cbd et de terpenes correspondant a la plante entiere et reste classee comme chanvre industriel
CA3007393C (fr) Composition veterinaire et ses procedes de production et d'utilisation
DE202023001867U1 (de) Formulierung umfassend mindestens eine Kresse-Art
US20230190781A1 (en) Ademetionine and cannabidiol based solid pharmaceutical composition and method for preparing it
CN100531777C (zh) 用于防治咽喉口腔疾病的组合物、其制剂及它们的制备方法
PL241381B1 (pl) Alkoholowy ekstrakt etanolowy z roślin z rodzaju Cannabis do zastosowania w preparatach zabezpieczających pszczoły przed szkodliwym działaniem insektycydów z grupy neonikotynoidów i zwalczających nosemozę
RU2659210C1 (ru) Способ коррекции антиоксидантного статуса новорожденных телят
RU2616841C1 (ru) Биологически активная добавка в капсулированной форме для дойных коров при интенсивной технологии содержания
RU2298920C1 (ru) Способ борьбы с нозематозом пчел
US20200022924A1 (en) Cannabidiol (CBD) Formulation Including Caprylic Acid
CN104382865A (zh) 注射用水溶性维生素药物组合物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180703

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190715

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/05 20060101ALI20190709BHEP

Ipc: A61K 36/185 20060101ALI20190709BHEP

Ipc: A61K 47/46 20060101ALI20190709BHEP

Ipc: A61K 9/12 20060101ALI20190709BHEP

Ipc: A61K 31/352 20060101ALI20190709BHEP

Ipc: A61K 45/06 20060101ALI20190709BHEP

Ipc: A61K 31/35 20060101AFI20190709BHEP

Ipc: A61K 47/26 20060101ALI20190709BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CANNA-B CURE LTD

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210115

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250211

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20250702

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: F10

Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251105

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016094019

Country of ref document: DE